Cargando…

Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer.

Safety of administration of a vindesine (VDS)-anti-CEA conjugate and its ability to localise after radiolabelling were investigated in patients with advanced metastatic carcinoma (4 colorectal and 4 ovarian). For imaging, patients received between 230 and 520 micrograms of 131I labelled antibody. In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ford, C. H., Newman, C. E., Johnson, J. R., Woodhouse, C. S., Reeder, T. A., Rowland, G. F., Simmonds, R. G.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1983
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011264/ https://www.ncbi.nlm.nih.gov/pubmed/6821632

Ejemplares similares

A vindesine-anti-CEA conjugate cytotoxic for human cancer cells in vitro.
por: Johnson, J. R., et al.
Publicado: (1981)

Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate.
por: Embleton, M. J., et al.
Publicado: (1983)

Cytotoxicity of etretinate and vindesine.
por: Gaukroger, J. M., et al.
Publicado: (1985)

Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model.
por: Sharma, S. K., et al.
Publicado: (1990)

Biochemical effects of vindesine.
por: Creasey, W. A.
Publicado: (1981)

Enhancement of cytotoxicity of vindesine and cis-platinum for human lung tumours by the use of verapamil in vitro.
por: Simmonds, A. P., et al.
Publicado: (1986)

The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody.
por: Pedley, R. B., et al.
Publicado: (1994)

A chlorambucil-anti-CEA conjugate cytotoxic for human colon adenocarcinoma cells in vitro.
por: Bernier, L. G., et al.
Publicado: (1984)

Prolonged localisation of a monoclonal antibody against CEA in a human colon tumour xenograft.
por: Harwood, P. J., et al.
Publicado: (1985)

Phase I study of 21 days continuous infusion with vindesine.
por: de Vries, E. G., et al.
Publicado: (1989)

Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
por: Pectasides, D., et al.
Publicado: (1989)

A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer.
por: Woods, R. L., et al.
Publicado: (1990)

Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA)--implications for targeted therapy.
por: Boxer, G. M., et al.
Publicado: (1994)

Vindesine receptors in cells of a human leukaemia cell line.
por: Totsuka, K., et al.
Publicado: (1982)

A comparison of the response of human lung carcinoma xenografts to vindesine and vincristine.
por: Evans, B. D., et al.
Publicado: (1982)

Localisation of gastrointestinal cancer with a 131 I labelled monoclonal antibody to CEA.
por: Allum, W. H., et al.
Publicado: (1986)

Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma--implications for radioimmunotherapy.
por: Boxer, G. M., et al.
Publicado: (1992)

Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine
por: Dhyani, Praveen, et al.
Publicado: (2022)

The effect of serum CEA on the distribution and clearance of anti-CEA antibody in a pancreatic tumour xenograft model.
por: Pedley, R. B., et al.
Publicado: (1989)

Characterisation of a vindesine-resistant human small-cell lung cancer cell line.
por: Ohta, S., et al.
Publicado: (1993)

The site of binding of anti-CEA antibodies to tumour CEA in vivo: an immunocytochemical and autoradiographic approach.
por: Moshakis, V., et al.
Publicado: (1982)

Carcinoembryonic antigen (CEA) expression and heterogeneity in primary and autologous metastatic gastric tumours demonstrated by a monoclonal antibody.
por: Hockey, M. S., et al.
Publicado: (1984)

Dose-dependent localisation and potential for therapy of F(ab')2 fragments against CEA studied in a human tumour xenograft model.
por: Rogers, G. T., et al.
Publicado: (1986)

Fractionated (131)I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice
por: Violet, J A, et al.
Publicado: (2008)

The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model.
por: Melton, R. G., et al.
Publicado: (1990)

Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine
por: Cha, Seung E., et al.
Publicado: (2021)

Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer
por: Sørensen, J B, et al.
Publicado: (1999)

Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results
por: Schoffelen, R, et al.
Publicado: (2013)

CEA Decline Predicts Tumor Regression and Prognosis in Locally Advanced Rectal Cancer Patients with Elevated Baseline CEA
por: Cai, Zerong, et al.
Publicado: (2020)

Carcinoembryonic antigen (CEA) "fingerprints".
por: Rule, A. H., et al.
Publicado: (1973)

Comparison of anti-fetal colonic microvillus and anti-CEA antibodies in peroperative radioimmunolocalisation of colorectal cancer.
por: Blair, S. D., et al.
Publicado: (1990)

Dosimetry and Gastrointestinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node Radiotherapy in Advanced Localised Prostate Cancer
por: Ferreira, M.R., et al.
Publicado: (2019)

First British standard for carcinoembryonic antigen (CEA).
por: Laurence, D. J., et al.
Publicado: (1975)

Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP).
por: Baldini, E., et al.
Publicado: (1998)

CEA solenoide
por: Sylvie Prodon
Publicado: (2003)

Toxicity and pharmacokinetic profile of SGM-101, a fluorescent anti-CEA chimeric antibody for fluorescence imaging of tumors in patients
por: Framery, Bérénice, et al.
Publicado: (2019)

Selection and characterisation of Affimers specific for CEA recognition
por: Shamsuddin, Shazana Hilda, et al.
Publicado: (2021)

Relationship of serum CEA levels to tumour size and CEA content in nude mice bearing colonic-tumour xenografts.
por: Lewis, J. C., et al.
Publicado: (1981)

In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
por: Blumenthal, R D, et al.
Publicado: (2008)

Localised Peritonitis
por: Baker, C. O.
Publicado: (1896)

Cannot write session to /tmp/vufind_sessions/sess_lt03fed3fgm4u2lbvolesodu94